LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…
Kate O’NeillSeptember 18, 2023
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease …
Kate O’NeillJuly 7, 2023
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from…
Kate O’NeillJune 1, 2023
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…
Kate O’NeillMay 3, 2023
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve…
Kate O’NeillMarch 29, 2023
Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and…
Kate O’NeillMarch 21, 2023
"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by…
Kate O’NeillMarch 2, 2023
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…
Kate O’NeillFebruary 23, 2023
The LuMind IDSC community and caregivers across the U.S. participated in “Challenges of Caregiving,” an…
adminJanuary 26, 2023